Mascoma Wealth Management’s Sarepta Therapeutics SRPT Stock Holding History

Mascoma Wealth Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-5	Closed	-$624	–	530
2024 Q3	$624	Hold	5	–	–	﹤0.01%	441
2024 Q2	$790	Hold	5	–	–	﹤0.01%	473
2024 Q1	$647	Hold	5	–	–	﹤0.01%	442
2023 Q4	$482	Hold	5	–	–	﹤0.01%	459
2023 Q3	$606	Hold	5	–	–	﹤0.01%	489
2023 Q2	$516	Hold	5	–	–	﹤0.01%	471
2023 Q1	$614	Hold	5	–	–	﹤0.01%	573
2022 Q4	$648	Hold	5	–	–	﹤0.01%	596
2022 Q3	$1K	Hold	5	–	–	﹤0.01%	588
2022 Q2	$0	Hold	5	–	–	﹤0.01%	638
2022 Q1	$0	Hold	5	–	–	﹤0.01%	604
2021 Q4	$0	Hold	5	–	–	﹤0.01%	561
2021 Q3	$0	Buy	+5	New	+$385	﹤0.01%	467
2021 Q2	–	Sell	-5	Closed	–	–	380
2021 Q1	$0	Buy	+5	New	+$461	﹤0.01%	464

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Mascoma Wealth Management's SRPT Position: Q4 2024 in Review

Mascoma Wealth Management sold out of Sarepta Therapeutics (SRPT) in Q4 2024, closing a stake of 5 shares — an estimated $624 sold.

Mascoma Wealth Management first reported a position in SRPT in Q1 2021 and held it in 14 quarters. The position peaked at $1K in Q3 2022. 464 funds tracked by Wall St. Rank hold SRPT as of Q4 2024.

Mascoma Wealth Management reported no remaining Sarepta Therapeutics position as of Q4 2024 after selling out during the quarter.
Mascoma Wealth Management sold 5 Sarepta Therapeutics shares in Q4 2024, an estimated $624.
Mascoma Wealth Management first reported a position in Sarepta Therapeutics in Q1 2021 and held it in 14 quarters.
Mascoma Wealth Management's Sarepta Therapeutics position peaked at $1K in Q3 2022.
464 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2024.

Based on Mascoma Wealth Management's 13F filing for Q4 2024, filed 10 Feb 2025.